Premium
Vaccines: SARS‐CoV‐2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination (Adv. Mater. 50/2020)
Author(s) -
Huang WeiChiao,
Zhou Shiqi,
He Xuedan,
Chiem Kevin,
Mabrouk Moustafa T.,
Nissly Ruth H.,
Bird Ian M.,
Strauss Mike,
Sambhara Suryaprakash,
Ortega Joaquin,
Wohlfert Elizabeth A.,
MartinezSobrido Luis,
Kuchipudi Suresh V.,
Davidson Bruce A.,
Lovell Jonathan F.
Publication year - 2020
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.202070373
Subject(s) - immunogen , virology , vaccination , neutralizing antibody , adjuvant , immunization , antibody , covid-19 , immune system , recombinant dna , antibody response , neutralization , virus , biology , immunology , medicine , monoclonal antibody , disease , pathology , infectious disease (medical specialty) , biochemistry , gene
In article number 2005637, Jonathan F. Lovell and co‐workers show that the SARS‐CoV‐2 RBD surface protein becomes a potent immunogen when presented in nanoparticle format. Using a vaccine adjuvant that spontaneously converts soluble recombinant antigens into stable particles, immunization studies in mice and rabbits shows that the particle‐based RBD elicits strong immune responses and potent antibodies capable of neutralizing the virus.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom